View Item 

Show simple item record

Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial

dc.contributor.authorSkoglund, Per H.en_US
dc.contributor.authorSvensson, Peren_US
dc.contributor.authorAsp, Jolineen_US
dc.contributor.authorDahlöf, Björnen_US
dc.contributor.authorKjeldsen, Sverre E.en_US
dc.contributor.authorJamerson, Kenneth A.en_US
dc.contributor.authorWeber, Michael A.en_US
dc.contributor.authorJia, Yanen_US
dc.contributor.authorZappe, Dion H.en_US
dc.contributor.authorÖstergren, Janen_US
dc.date.accessioned2015-03-05T18:24:41Z
dc.date.available2016-04-01T15:21:07Zen
dc.date.issued2015-02en_US
dc.identifier.citationSkoglund, Per H.; Svensson, Per; Asp, Joline; Dahlöf, Björn ; Kjeldsen, Sverre E.; Jamerson, Kenneth A.; Weber, Michael A.; Jia, Yan; Zappe, Dion H.; Östergren, Jan (2015). "Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial." The Journal of Clinical Hypertension 17(2): 141-146.en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110751
dc.publisherWiley Periodicals, Inc.en_US
dc.titleAmlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trialen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110751/1/jch12460.pdf
dc.identifier.doi10.1111/jch.12460en_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreferenceRedon J. The importance of 24‐hour ambulatory blood pressure monitoring in patients at risk of cardiovascular events. High Blood Press Cardiovasc Prev. 2013; 20: 13 – 18.en_US
dc.identifier.citedreferenceBenetos A, Zureik M, Morcet J, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol. 2000; 35: 673 – 680.en_US
dc.identifier.citedreferenceSafar ME. Pulse pressure, heart rate, and drug treatment of hypertension. Curr Hypertens Rep. 2004; 6: 190 – 194.en_US
dc.identifier.citedreferenceMancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31: 1281 – 1357.en_US
dc.identifier.citedreferenceJames PA, Oparil S, Carter BL, et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507 – 520.en_US
dc.identifier.citedreferenceFrohlich ED, Grim C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometers. Hypertension. 1988; 11: 210A – 222A.en_US
dc.identifier.citedreferenceWeber MA, Bakris GL, Hester A, et al. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013; 126: 501 – 508.en_US
dc.identifier.citedreferenceDahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995 – 1003.en_US
dc.identifier.citedreferenceFyhrquist F, Dahlöf B, Devereux RB, et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 2005; 45: 580 – 585.en_US
dc.identifier.citedreferenceErnst ME. Ambulatory blood pressure monitoring: recent evidence and clinical pharmacy applications. Pharmacotherapy. 2013; 33: 69 – 83.en_US
dc.identifier.citedreferenceVlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all‐cause mortality with central haemodynamics: a systematic review and meta‐analysis. Eur Heart J. 2010; 31: 1865 – 1871.en_US
dc.identifier.citedreferenceProtogerou AD, Stergiou GS, Vlachopoulos C, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class‐effects of antihypertensive drugs on pressure amplification. Curr Pharm Des. 2009; 15: 272 – 289.en_US
dc.identifier.citedreferenceStaessen JA, Fagard R, Thijs L, et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet. 1997; 350: 757 – 764.en_US
dc.identifier.citedreferenceStaessen JA, Thijs L, O'Brien ET, et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens. 2002; 1 ( 10 pt 1 ): 835 – 843.en_US
dc.identifier.citedreferenceSvensson P, de Faire U, Niklasson U, Ostergren J. Office blood pressure underestimates ambulatory blood pressure in peripheral arterial disease in comparison to healthy controls. J Hum Hypertens. 2004; 18: 193 – 200.en_US
dc.identifier.citedreferenceJamerson KA, Devereux R, Bakris GL, et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24‐hour ambulatory systolic blood pressure control. Hypertension. 2011; 57: 174 – 179.en_US
dc.identifier.citedreferenceGasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta‐analysis of clinical trial control groups. J Hypertens. 2002; 20: 145 – 151.en_US
dc.identifier.citedreferenceGlynn RJ, Chae CU, Guralnik JM, et al. Pulse pressure and mortality in older people. Arch Intern Med. 2000; 160: 2765 – 2772.en_US
dc.identifier.citedreferenceVaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol. 2001; 88: 980 – 986.en_US
dc.identifier.citedreferenceHadaegh F, Shafiee G, Hatami M, Azizi F. Systolic and diastolic blood pressure, mean arterial pressure and pulse pressure for prediction of cardiovascular events and mortality in a Middle Eastern population. Blood Press. 2012; 21: 12 – 18.en_US
dc.identifier.citedreferenceMiura K, Dyer AR, Greenland P, et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25‐year cardiovascular and all‐cause mortality rates: the Chicago Heart Association Detection Project in Industry Study. Hypertension. 2001; 38: 232 – 237.en_US
dc.identifier.citedreferenceAsmar R, Safar M, Queneau P. Pulse pressure: an important tool in cardiovascular pharmacology and therapeutics. Drugs. 2003; 63: 927 – 932.en_US
dc.identifier.citedreferenceEzzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360: 1347 – 1360.en_US
dc.identifier.citedreferenceRapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life‐years lost, and age‐specific associations in 1.25 million people. Lancet. 2014; 383: 1899 – 1911.en_US
dc.identifier.citedreferenceJamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high‐risk patients. N Engl J Med. 2008; 359: 2417 – 2428.en_US
dc.identifier.citedreferenceJamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first‐line combination therapies in hypertension. Am J Hypertens. 2004; 17: 793 – 801.en_US
dc.identifier.citedreferenceFranklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham heart study. Circulation. 2001; 103: 1245 – 1249.en_US
dc.identifier.citedreferenceMadhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994; 23: 395 – 401.en_US
dc.identifier.citedreferenceMitchell GF, Moyé LA, Braunwald E, et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation. 1997; 96: 4254 – 4260.en_US
dc.identifier.citedreferenceBenetos A, Safar M, Rudnichi A, et al. Pulse pressure: a predictor of long‐term cardiovascular mortality in a French male population. Hypertension. 1997; 30: 1410 – 1415.en_US
dc.identifier.citedreferenceMillar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens. 1999; 17: 1065 – 1072.en_US
dc.identifier.citedreferenceAvanzini F, Alli C, Boccanelli A, et al. High pulse pressure and low mean arterial pressure: two predictors of death after a myocardial infarction. J Hypertens. 2006; 24: 2377 – 2385.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jch12460.pdf
Size:
142.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.